InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Thursday, August 6, 2026, at 9:00 AM EST

written by InvestorNews | August 5, 2026

InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, August 6, 2026, at 9:00 AM EST, featuring Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Voyageur is developing barium and iodine active pharmaceutical ingredients and imaging contrast agents, with a goal of vertically integrating the barium, iodine and endohedral fullerene (C60) drug markets. The Company has developed five barium contrast products licensed by Health Canada and plans to generate cash flow through partnerships with established Canadian GMP pharmaceutical manufacturers, supporting regulatory validation and market entry. Voyageur owns 100% of the Frances Creek barium sulfate project, which hosts high-grade barite targeted for pharmaceutical use. Management believes Frances Creek can support higher-quality, lower-cost imaging products than synthetic barium sulfate. Voyageur’s long-term strategy is to control input costs and become a domestic radiology drug manufacturer.

In preparation for tomorrow’s InvestorTalk, here are some recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:

  • July 17, 2026 – Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker – click here
  • June 23, 2026 – Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility – click here
  • June 18, 2026 – Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway – click here
  • June 10, 2026 – Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project – click here

We found the June 23rd news release titled, “Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility” particularly noteworthy and here are 5 key data points from it:

  • Fluor Engaged for Feasibility Studies – Voyageur Pharmaceuticals has engaged Fluor Corporation to complete feasibility studies for two projects supporting its vertically integrated North American contrast media supply chain.
  • Oklahoma Iodine Production Facility Planned – One study covers a proposed iodine extraction and production facility in Oklahoma, using Voyageur’s patent-pending Meuller process to produce high-purity iodine from iodine-rich oilfield brine.
  • Integrated Contrast Drug Facility Being Studied – The second study covers Voyageur’s planned integrated iodine and barium contrast drug manufacturing facility, expected to produce finished barium and iodine-based contrast media products.
  • US$2.35M Budgeted for Bayer Project Study – Voyageur has budgeted US$2,350,000 for the Bayer project feasibility study, with a final budget for the integrated drug facility study to be set after testing its proprietary Streamline iodine drug manufacturing process.
  • Potential 2027 Construction Decision – The studies are expected to be completed in early 2027, paving the way for a potential construction decision in 2027, subject to study results and further agreements.

For more information on Voyageur Pharmaceuticals Ltd., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.